Clinical patterns of juvenile idiopathic arthritis in Zambia

James Chipeta1, Panganani Njobvu, Somwe Wa-Somwe

  • 1Department of Paediatrics and Child Health, University of Zambia School of Medicine, P,O, Box 50110, Lusaka, Zambia. jameschipeta@smuth-mru.org.zm.

Insights

Juvenile idiopathic arthritis (JIA) in Zambia is primarily polyarticular rheumatoid factor negative. This study highlights late presentation as a significant challenge for pediatric arthritis patients in the region.

Area of Science:

  • Rheumatology
  • Pediatrics
  • Epidemiology

Background:

  • Juvenile idiopathic arthritis (JIA) is a diverse autoimmune condition with limited reported data in Sub-Saharan Africa.
  • Understanding JIA clinical patterns in indigenous African populations is crucial for accurate diagnosis and management.

Purpose of the Study:

  • To describe the clinical characteristics and subtypes of Juvenile idiopathic arthritis (JIA) in Zambian children.
  • To identify epidemiological trends and challenges in JIA diagnosis and care in Zambia.

Main Methods:

  • Retrospective review of hospital records for patients aged 16 years or younger with chronic arthritis from 1994-1998 and 2006-2010 at the University Teaching Hospital, Lusaka.
  • Classification of patients using the International League of Associations for Rheumatology (ILAR) JIA diagnostic criteria.
  • Separate assessment of HIV-seropositive patients.

Main Results:

  • Polyarticular rheumatoid factor negative JIA was the most common subtype (34.62%), followed by oligoarthritis (32.05%).
  • The average age at onset was 8.7 years, with a female to male ratio of 1.2:1.
  • Late presentation to the hospital was noted, with an average age of 11.3 years at first visit.

Conclusions:

  • Juvenile idiopathic arthritis in Zambia predominantly presents as a polyarticular rheumatoid factor negative disease.
  • Late diagnosis and presentation pose significant challenges for patient management and educational support.
  • Further research into the genetic and environmental factors influencing JIA in this region is warranted.
Abstract

Related Concept Videos

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Development of the Limb Synovial Joints01:07

Development of the Limb Synovial Joints

Joints form during embryonic development in conjunction with the formation and growth of the associated bones. The embryonic tissue that gives rise to all bones, cartilage, and connective tissues of the body is called mesenchyme.
The mesenchymal stem cells differentiate into chondrocytes that form the hyaline cartilage, and later the cartilaginous model of the bone. This model further transforms into a bone. This process is known as endochondral ossification.
During development, the limbs...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Patterns of Fever01:26

Patterns of Fever

Before understanding the types and patterns of fever, it is essential to know its phases.